TIGP (BIO)—AI, Systems Glycobiology, and Immunology: A Trifecta for Advancing Medical Discovery and Transforming Medicine
演講時間變更
- 2023-12-15 (Fri.), 10:00 AM
- 僅線上視訊｜視訊連結請見摘要
- 英文演講｜講者簡介請見附件
- Dr. Wan-Tien (Austin) Chiang (江萬田博士)
- Immunology Center of Medical College of Georgia , Augusta University, USA
Abstract
Glycosylation profoundly impacts the activity, stability, and pharmacokinetics of biopharmaceuticals, holding tremendous potential to enhance the efficacy of protein-based therapeutics. The increasing global demand for cost-effective, large-scale biopharmaceuticals to combat life-threatening diseases hinges on overcoming two critical challenges: precise control of glycan structures on the therapeutics and the development of robust mammalian cell lines for producing therapeutics. We address the knowledge gap in rational glycoengineering and its impact on host cells. Specifically, we investigated a large panel of glycoengineered CHO cell clones, employing a multidimensional approach involving glycoprofiling, quantification of bioprocessing phenotypes, and RNA-Seq expression profiling. We demonstrate the capacity to achieve specific glycoforms by manipulating dominant glycosyltransferases responsible for N-linked glycosylation in CHO cells. Interestingly, we also found that glycoengineering exerts a profound influence on cell phenotype, activating diverse cellular pathways. Our research represents a significant milestone, unraveling the intricate cellular responses induced by glycoengineering in host cells involved in recombinant protein drug production. In the future, the synergy between AI, Systems Glycobiology, and Immunology promises to revolutionize medical discovery and medicine, offering innovative pathways for cost-effective, potent biopharmaceutical development to address the critical healthcare needs of millions globally.
附件下載
最後更新日期：2023-12-04 10:45
回列表頁
